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Abstract
Purpose:  To  investigate  the  effects  of  injectable  hormonal  contraceptives  on  tear  secretion  and
tear stability  of  females  within  child  bearing  age  in  Nigeria.
Methods: The experimental  group  consisted  of  32  healthy  females  (mean  age  was  34.72  ±  5.44)
on injectable  hormonal  contraceptives;  and  the  control  group  comprised  32  females  (mean
age was  34.66  ±  5.24)  who  were  not  on  hormonal  contraceptives.  The  tear  stability  and  tear
secretion were  measured  using  the  non-invasive  tear  break  up  time  (NITBUT)  technique  and
Schirmer’s strips,  respectively.  All  the  females  were  at  follicular  phase  of  menstrual  cycle.  The
plasma levels  of  progesterone  and  estradiol  of  all  subjects  were  determined.
Results: There  were  no  remarkable  effects  of  injectable  hormonal  contraceptives  on
tear secretion  (P  =  0.929)  and  tear  stability  (P  =  0.814).  There  were  weak  correla-
tions between  the  plasma  levels  of  progesterone  and  tear  secretion  (r  =  −0.232,
P >  0.05),  as  well  as  with  tear  stability  (r  =  −0.322,  P  >  0.05).  Also,  there  were  weak  positive
correlation  between  plasma  levels  of  estradiol  and  tear  secretion  (r  =  0.304,  P  >  0.05),  as  well
as with  tear  stability  (r  =  0.262,  P  >  0.05).  There  were  no  signiﬁcant  differences  in  tear  stability
between the  experimental  and  control  groups  (P  >  0.05).
Conclusions:  Injectable  hormonal  contraceptives  had  no  signiﬁcant  effects  on  tear  secretion
and tear  stability  of  healthy  women  of  childbearing  age.  Further  studies  may  be  required  to
determine the  effects  of  hormonal  contraceptives  on  tear  volume  and  stability  of  women  with
dry eyes.
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Secreción  y  estabilidad  de  la  lágrima  en  mujeres  sometidas  a  anticoncepción
hormonal
Resumen
Objetivo:  El  estudio  tuvo  como  objetivo  la  investigación  de  los  efectos  de  los  anticonceptivos
hormonales  inyectables  sobre  la  secreción  y  la  estabilidad  de  la  lágrima  en  mujeres  en  edad
fértil en  Nigeria.
Métodos:  El  grupo  experimental  estaba  compuesto  por  32  mujeres  sanas  (edad  media  de  34,72  ±
5,44 an˜os)  sometidas  a  terapia  anticonceptiva  hormonal  inyectable;  y  el  grupo  de  control  incluía
a 32  mujeres  (edad  media  de  34,66  ±  5,24  an˜os)  no  sometidas  a  anticoncepción  hormonal.  La
estabilidad  y  la  secreción  de  la  lágrima  se  midieron  mediante  la  técnica  NITBUT  (tiempo  de
ruptura de  la  capa  lipídica  de  la  lágrima)  y  las  tiras  de  Schirmer,  respectivamente.  Todas  las
mujeres  se  hallaban  en  la  fase  folicular  del  ciclo  menstrual.  Se  determinaron  los  niveles  de
progesterona  y  de  estradiol  de  todas  las  pacientes.
Resultados: No se  hallaron  efectos  destacables  de  los  anticonceptivos  hormonales  inyectables
sobre la  secreción  (P=0,929)  y  la  estabilidad  de  la  lágrima  (P=0,814).  Se  produjeron  correla-
ciones leves  entre  los  niveles  de  plasma  de  la  progesterona  y  la  secreción  de  la  lágrima  (r=-0,232,
P>0,05), y  la  estabilidad  de  la  lágrima  (r=-0,322,  P>0,05).  También  se  halló  una  débil  correlación
entre los  niveles  de  plasma  del  estradiol  y  las  secreción  de  la  lágrima  (r=0,304,  P>0,05),  y  la
estabilidad  de  la  lágrima  (r=0,262,  P>0,05).  No  se  produjeron  diferencias  signiﬁcativas  en  cuanto
a estabilidad  de  la  lágrima  entre  los  grupos  experimental  y  de  control  (P  >  0,05).
Conclusiones: Los anticonceptivos  hormonales  inyectables  no  tienen  efectos  signiﬁcativos  sobre
la secreción  y  la  estabilidad  de  la  lágrima  en  las  mujeres  sanas  en  edad  fértil.  Pueden  precisarse
estudios  adicionales  para  determinar  los  efectos  de  los  anticonceptivos  hormonales  sobre  el
volumen y  la  estabilidad  de  la  lágrima  en  mujeres  con  ojo  seco.
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he  endocrine  system  exerts  signiﬁcant  inﬂuences  on  the
hysiology  and  pathophysiology  of  the  lacrimal  gland.  Andro-
ens,  estrogens  and  progestin  have  been  identiﬁed  in  the
ear  ﬁlm  and  their  levels  in  the  tears  appeared  to  corre-
ate  with  those  of  the  serum.1 Receptors  for  androgens,
strogens,  progesterone  and  prolactin  have  been  found  in
everal  ocular  tissues  of  rats,  rabbits  and  humans.  These
ormones  regulate  the  immune  system,  secretary  functions
f  lacrimal  and  the  meibomian  glands.2,3 Thus  the  eye  is
 target  organ  for  sex  hormones.  Rocha  et  al.4 reported
hat  androgen,  estrogen  and  progesterone  receptors  mRNAs
ere  present  in  the  epithelial  cells  of  the  lacrimal  gland,
eibomian  gland,  lid,  palpebral  and  bulbar  conjunctivae,
ornea,  uveal  body,  lens,  and  retina  of  humans.  These  obser-
ations  demonstrate  that  sex  steroid  receptors  mRNAs  exist
n  a  variety  of  ocular  tissues.  It  was  suggested  that  these
eceptors  in  the  eye  might  be  target  sites  for  androgens,
strogen  and  progestin;  and  that  these  sites  might  also
e  susceptible  to  administered  topical  and  systemic  hor-
onal  contraceptives.  Several  authors  reported  that  these
ex  steroids  (i.e.  androgens,  estrogens  and  progestin)  modu-
ate  the  structural  characteristics,  functional  attributes  and
athological  features  of  ocular  tissues.  These  observations
ad  accounted  for  the  gender-related  differences  in  dry
yes.5--7
Injectable  contraceptives  are  hormone  shots  adminis-
ered  to  some  women  in  order  to  prevent  pregnancy.  An
stimated  16  million  women  throughout  the  world  use
ormonal  contraceptives.8 There  are  controversies  on  the
ffects  of  the  injectable  hormonal  contraceptives  on  tear
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hysiology  and  tear  production  of  women.  Sullivan  et  al.3
uggested  that  hormonal  contraceptives  improved  the  qual-
ty  and  the  production  of  tear  ﬁlm,  but  other  authors9
eported  that  the  hormone  increases  the  risk  of  dry  eyes  in
omen.  Some  researchers10--12 proposed  also  that  either  the
opical  or  systemic  application  of  estrogens  might  amelio-
ate  the  symptoms  of  dry  eyes.  There  were  other  suggestions
hat  oral  contraceptives  containing  estrogen  might  decrease
ear  volume  and  reduce  tear  break-up  time.  It  was  also
uspected  that  estrogen  oral  contraceptives  might  atten-
ate  mucous  production,  increase  foreign  body  sensation,
educe  contact  lens  intolerance,  decrease  visual  acuity  and
ncrease  the  risk  of  dry  eyes  in  women  using  the  drugs.3,13,14
t  has  been  recorded  that  post-menopausal  women  under
ormone  replacement  therapy  (HRT),  particularly  estrogen
lone,  were  at  risk  of  dry  eyes  syndrome.9 These  controver-
ies  prompted  this  study,  aimed  at  investigating  the  effects
f  injectable  contraceptives  on  tear  secretion  and  stability
f  women  within  child  bearing  ages.
ethods
he  study  was  a  prospective  study  carried  out  in  the  Depart-
ent  of  Optometry,  University  of  Benin,  Benin  City,  Nigeria.
he  participants  comprised  sixty  four  (64)  healthy  women  of
hild  bearing  ages,  within  the  age  bracket  of  26--45  years.
hey  were  healthy  female  volunteers  from  the  family  plan-
ing  clinic,  Department  of  Obstetrics  and  Gynaecology,  Uni-
ersity  of  Benin  teaching  hospital,  Benin  City,  Nigeria.  The
ubjects  consisted  of  32  females,  who  were  current  users
f  injectable  contraceptives.  The  control  group  consisted
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of  32  females  who  had  not  used  any  form  of  hormonal  con-
traceptives.  The  control  and  the  experimental  groups  were
properly  matched  for  age  (within  3  months  to  one  year  dif-
ferences  in  age)  and  the  phase  of  menstrual  cycle.  All  the
subjects  were  Nigerians  living  in  Edo  and  Delta  states  of
Nigeria.  Informed  and  verbal  consents  were  obtained  from
each  of  the  participants  and  the  study  was  conducted  in
accordance  with  the  tenants  of  the  Declaration  of  Helsinki.
Questionnaires  were  administered  to  the  subjects  in
order  to  obtain  information  about  their  personal  data,  the
use  of  injectable  contraceptives  and  other  forms  of  con-
traceptives,  the  type  of  contraceptive  used,  duration  of
use,  oculo-visual  history,  and  general  health  history.  Oral
interviews  were  carried  out  for  subjects  who  were  not
able  to  ﬁll  out  the  questionnaires,  which  were  ﬁlled  for
them.  A  brief  case  history  was  obtained  from  each  sub-
ject.  The  subjects’  ocular  health  and  general  health  history
were  obtained.  Visual  acuity  test  was  carried  out  using  the
standard  Snellen’s  chart.  External  eye  examination  was  car-
ried  out,  using  the  slit  lamp  biomicroscope  to  rule  out  ocular
surface  and  anterior  segment  abnormalities.  The  internal
structures  of  the  eyes  were  properly  examined  with  a  direct
ophthalmoscope  to  rule  out  diseases  of  the  posterior  seg-
ment.  Blood  pressure  was  measured  with  the  use  of  a
sphygmomanometer  to  rule  out  hypertensive  patients  from
the  study.  Participants  who  met  the  inclusion  criteria  were
either  put  in  the  experimental  group,  if  they  were  users  of
injectable  hormonal  contraceptives  or  in  the  control  groups,
and  if  they  were  not  on  hormonal  contraceptives.  These
subjects  were  identiﬁed  with  serial  numbers.
Inclusion  criteria  for  the  experimental  and  the
control groups
Women  of  child  bearing  age,  within  26--45  years  of  age,
who  were  only  on  injectable  birth  control  hormones  (such  as
Depo-Provera:  150  mg  depot  medroxyprogesterone  acetate,
Noristerat:  200  mg  noresthisterone  enanthate  ‘NET-EN’)  for
at  least  a  period  of  six  months  and  in  the  follicular  phase  of
menstrual  cycle  were  enrolled  in  the  experimental  group.
The  control  group  consisted  of  females  between  26  and  45
years  of  age  who  were  either  not  on  contraceptives  or  were
not  on  hormonal  contraceptives.  All  the  female  participants
were  in  the  follicular  phase  of  the  menstrual  cycle.
Exclusion  criteria
Women  with  lid-gland  dysfunction  (blepharitis)  ocular  sur-
face  abnormalities  and  any  other  obvious  ocular  pathology
were  excluded  from  the  study.  Women  with  history  of  any
systemic  disease,  ocular  surgery,  laser  therapy  and  on
any  medications  were  not  included  in  the  study.  Contact
lenses  wearers,  pregnant  women,  smokers,  women  under
topical  eye  drops,  menopausal  and  post-menopausal  women
were  also  excluded.Measurement  of  tear  secretion
Total  tear  secretion  (without  anesthetic)  was  measured  with
Schirmer’s  test  strip  on  the  subject’s  right  eye,  which  was
r
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ently  dried  to  remove  any  excess  tears.  The  subject  was
omfortably  seated  and  was  instructed  to  look  up,  while  the
ower  lid  was  gently  pulled  down.  The  bent  hooked  end  of
he  Schirmer’s  strip  was  then  placed  at  the  junction  of  the
iddle  and  outer  two  third  of  the  lower  lid,  with  care  not  to
ouch  the  cornea  or  lashes.  The  subject  was  asked  to  con-
inuously  look  up  and  blink  normally  or  to  close  the  eye  if
t  was  more  comfortable,  but  not  to  squeeze  the  eye.  The
trip  was  removed  5  min  after  insertion.  The  wet  portion
f  the  strip  from  the  bent  notch  was  measured  in  mm  and
ecorded.  Three  readings  were  taken  for  the  sake  of  reli-
bility  with  10  min  interval  between  readings.  The  average
f  these  readings  was  recorded  for  each  subject  and  any
alue  less  than  10  mm  of  wetting  after  5  min  was  considered
bnormal.
easurement  of  tear  stability
he  NITBUT  was  employed  in  the  assessment  of  tear  ﬁlm
tability  for  both  eyes.  When  the  subject  and  the  exam-
ner  were  comfortably  seated,  the  subject  was  asked  to  look
hrough  the  eyepiece,  while  necessary  adjustments  on  the
eratometer  were  carried  out  until  the  mires  were  visible.
he  subject  was  instructed  to  blink  and  to  keep  the  eye
pen.  The  time  between  the  last  blink  and  the  doubling
r  distortion  of  the  mires  was  recorded  with  a  stopwatch.
he  mean  value  for  three  readings  was  recorded  for  the
ITBUT  and  dry  eye  was  suspected  for  any  value  lesser
han  10  s.
lood  sample  collection
lood  samples  were  collected  into  labeled  (with  serial
umber  for  identiﬁcation)  specimen  tubes  (without  antico-
gulant)  and  they  were  left  to  stand  at  room  temperature
37 ◦C)  for  1  h.  The  blood  was  then  centrifuged  at  full  speed
n  a  micro  centrifuge.  The  supernatant  was  removed  and
laced  in  a  new  specimen  tube.  The  serum  was  stored  at
20 ◦C  (for  long  term  storage)  prior  to  the  analysis.
ormonal  assay
he  plasma  levels  of  progesterone  and  estrogen  (estra-
iol)  were  assessed  using  Microwell  Progesterone  EIA
REF-4210-96)  and  Microwell  Estradiol  EIA  (REF-5026-70),
espectively.
tatistical  analysis
he  data  was  analyzed  with  STATGRAPHICS  plus  5.1,  Stu-
ent’s  unpaired  t-test  was  used  to  determine  the  effect  of
njectable  contraceptive  on  tear  secretion  in  the  control
nd  experimental  groups  and  tear  stability  in  the  control
nd  experimental  groups.  Pearson’s  correlation  analysis  and
egression  was  used  to  determine  the  correlations  between
lasma  levels  of  estrogen  and  progesterone  with  the  tear
ecretion  and  tear  stability.  The  results  were  signiﬁcant  if
he  probability  values  revealed  P  <  0.05.
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Table  1  Expected  normal  values  of  progesterone  and
estradiol  for  females.
Phase  Progesterone
(ng/mL)
Estradiol  (pg/mL)
Follicular  0.10--1.60  24--138
Luteal  2.50--32.0  19--164
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erum  levels  of  progesterone  and  estradiol
he  expected  normal  values  of  progesterone  and  estradiol
re  shown  in  Table  1.
The  mean  serum  levels  of  progesterone  and  estradiol
btained  in  this  study  were  within  expected  values  given
n  Table  1.
Table  2  shows  that  there  were  signiﬁcantly  higher  serum
rogesterone  levels  in  the  experimental  group  than  was
ound  in  the  control  group  (P  <  0.05).
The  mean  estradiol  level  in  the  control  group  was  higher
han  that  of  the  experimental  group,  but  there  were  no
tatistically  signiﬁcant  differences  between  these  values
P  >  0.05).
ear  secretion
he  mean  total  tears  secretion  in  mm  per  5  min  in  the  exper-
mental  and  control  groups  were  20.12  ±  7.58  mm/5  min  and
0.28  ±  6.41  mm/5  min,  respectively  (Table  3).  There  were
o  signiﬁcant  differences  in  these  values  (P  =  0.929),  using
npaired  t-test.
Fig.  1  shows  that  there  were  weak  correlations  between
he  plasma  levels  of  progesterone  and  tear  secretion
r  =  −0.232),  although  this  was  not  statistically  signiﬁcant
P  >  0.05).
There  were  weak  positive  correlations  between  the
lasma  levels  of  estradiol  and  tear  secretion  (r  =  0.304)
Mean serum progesterone (ng/mL)
Total tear secretion = 27.185 - 4.593 x progesterone, r = - 0.232
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igure  1  Scatter  plot  showing  the  relationship  between  tear
ecretion  and  serum  progesterone  levels  for  the  experimental
roup  with  the  95%  conﬁdence  interval  of  the  regression.
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ith the  95%  conﬁdence  interval  of  the  regression.
lthough  this  was  also  not  statistically  signiﬁcant  (P  >  0.05)
Fig.  2).
ear  stability
he  mean  NITBUT  for  experimental  and  control  groups  were
5.41  ±  4.27  s  and  15.66  ±  4.17  s,  respectively.
The  unpaired  t-test  revealed  also  that  there  were  no  sig-
iﬁcant  differences  between  the  NITBUT  for  experimental
nd  control  groups  (P  =  0.814)  (Table  3).
Fig.  3  shows  that  there  was  a  weak  negative  correlation
etween  tear  stability  and  serum  levels  of  proges-
erone  in  the  experimental  group  (r  =  −0.322,  P  >  0.05)
hich  was  not  statistically  signiﬁcant.  There  was  also  a  non
tatistically  signiﬁcant  weak  positive  correlation  between
ear  stability  and  serum  levels  of  estradiol  (r  =  0.262,
 >  0.05)  (Fig.  4).
iscussionears  lubricate,  nourish  and  protect  the  eyes  from  dust,  irri-
ants  and  infections.  Tears  also  keep  the  surface  of  the  eye
ptically  clear  and  smooth.  The  imbalances  in  the  compo-
ition  of  tears,  may  either  decrease  tear  production  or
Mean serum progesterone (ng/mL)
NITBUT = 20.923 - 3.589 x progesterone, r = - 0.322
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igure  3  Scatter  plot  showing  the  relationship  between  tear
tability  and  serum  progesterone  levels  for  experimental  group
ith the  95%  conﬁdence  interval  of  the  regression.
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Table  2  Mean  levels  of  progesterone  and  estradiol.
Age  range  Experimental  group  Control  group
n  Mean  serum
progesterone
(ng/mL)
Mean  serum
estradiol
(pg/mL)
n  Mean  serum
progesterone
(ng/mL)
Mean  serum
estradiol
(pg/mL)
26--30  10  1.51  ±  0.33  59.80  ±  7.30  10  0.82  ±  0.23  66.80  ±  9.25
31--35 7  1.59  ±  0.42  53.43  ±  12.46  8  0.50  ±  0.42  54.62  ±  7.40
36--40 10  1.62  ±  0.40  43.90  ±  7.26  8  0.47  ±  0.36  49.25  ±  14.18
41--45 5 1.34 ±  0.45  32.00 ±  5.70  6  0.18  ±  0.17  43.33  ±  10.41
Total 32  1.54  ±  0.38  49.09  ±  12.73  32  0.53  ±  0.38  54.97  ±  13.41
n: number.
Table  3  Mean  values  of  tear  secretion  and  tear  stability  in  different  age  groups.
Age  range  Experimental  group  Control  group
n Mean  NITBUT  (s) Mean  total  tear
secretion
(mm/5  min)
n Mean  NITBUT  (s) Mean  total  tear
secretion
(mm/5  min)
26--30  10  17.70  ±  5.71  23.70  ±  10.25  10  17.90  ±  5.60  24.90  ±  8.05
31--35 7  15.29  ±  3.59  21.86  ±  6.57  8  15.25  ±  3.01  19.12  ±  2.48
35--40 10  14.00  ±  2.86  16.50  ±  5.02  8  14.88  ±  2.42  18.12  ±  6.24
41--45 5 13.80  ±  3.03  17.80  ±  3.27  6  13.50  ±  3.67  17.00  ±  3.16
Total 32  15.41  ±  4.27  20.12  ±  7.58  32  15.66  ±  4.17  20.28  ±  6.41
n: number.
encourage  excessive  tear  evaporation.  This  situation  can
lead  to  tear  ﬁlm  dysfunction,  usually  diagnosed  as  ‘‘dry
eye’’.15
The  results  of  this  study  revealed  that  there  were
no  signiﬁcant  differences  in  the  tear  secretion  (P  =  0.92)
and  tear  stability  (P  =  0.81)  between  women  on  injectable
hormonal  contraceptives  and  women  not  using  hormonal
contraceptives  (P  >  0.05).  The  results  were  consistent  with
the  observations  of  Tomlinson  et  al.16 who  carried  out  a  sim-
ilar  study  on  the  effects  of  oral  hormonal  contraceptives  on
tear  physiology.  They16 reported  that  the  oral  contraceptives
had  no  effect  on  normal  tear  physiology.  The  observations
Mean serum estradiol (pg/mL)
NITBUT = 11.080 + 0.088 x estradiol, r = 0.262
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Figure  4  Scatter  plot  showing  the  relationship  between  tear
stability  and  serum  estradiol  level  for  the  experimental  group
with the  95%  conﬁdence  interval  of  the  regression.
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vn  this  study  also  agree  with  that  of  Kuscu  et  al.17 who  found
hat  HRT  had  no  effect  on  tear  function  in  post  menopausal
omen.  They17 concluded  that  their  observation  was  the
esult  of  the  high  levels  of  tear  lysozyme  and  IgA  in  post
enopausal  women,  using  HRT.  Taner  et  al.18 found  also
hat  there  were  no  obvious  changes  in  tear  ﬁlm  break  up
ime  and  Schirmer’s  test  values  in  females  on  HRT.  However,
ltintas¸  et  al.19 observed  some  increase  in  the  tear  quality
nd  quantity  of  women  who  had  been  on  two  years  of  HRT.
he  observations  of  Altintas¸  et  al.19 were  different  from  that
f  this  study.
It  was  observed  that  an  increase  in  serum  proges-
erone  resulted  in  slight  decrease  in  tear  stability  but  there
ere  no  signiﬁcant  correlations  between  the  serum  lev-
ls  of  progesterone  and  tear  stability  (r  =  −0.322,  P  >  0.05).
here  were  also  no  signiﬁcant  correlations  between  the
erum  level  of  progesterone  and  tear  secretion  (r  =  −0.232,
 >  0.05).
In  overall,  injectable  hormonal  contraceptives  had  no  sig-
iﬁcant  effect  on  tear  secretion  and  stability  on  women  of
hild  bearing  age.  It  was  also  observed  that  there  were  no
bvious  correlations  between  the  serum  levels  of  hormones
nd  tear  volume  and  the  serum  levels  of  hormones  and
ear  stability.  Therefore,  this  study  shows  that  injectable
ormonal  contraceptives  have  no  effect  on  tear  produc-
ion  and  tear  quality  in  healthy  women  of  child  bearing
ge.
However,  further  studies  may  be  required  to  investigate
he  short  term  effects  of  hormonal  contraceptives  on  tear
olume  and  stability  of  women  with  dry  eyes.
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